An International Randomized Controlled Trial (With Videos)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Around the Globe Israeli Medical Association No
Around The Globe Israeli Medical Association No. 16 | June 2011 A word from the chairman Dear Friends, vices to those from evacuated areas who and opinions on professional issues as e are happy to present you had no access to medical care. well as on the unbalanced exposures and with another issue of ‘IMA I had the pleasure of travelling to discussions of political topics concerning around the Globe’ where the UK, and met our Jewish Medical As- Israel in the British scientific Journals. I Wyou can read about the work of the IMA sociation - UK Chapter. I met medical would like to thank the IMA UK Chapter in Israel and abroad. In February, the students affiliated with the IMA and re- for their generous hospitality during my IMA publically announced our launch viewed Neuroscience practice in Israel. time in London. of “a mission to save public medicine,” I attended an evening event hosted by I am excited to inform you that we demanding additional manpower, more Dr. David Katz, the executive chairman have been invited to present Israeli and beds in hospitals, and incentive pay to of the UK Chapter, which was attended Jewish Medicine at the European Par- draw more physicians to the periphery by the local IMA-WF committee group. liament this November. I would like to and to multiple specialties suffering Throughout the evening we discussed thank Dr. Willie Lipschutz, the executive from physician shortages. This struggle issues related to how Israeli medicine chairman of the Belgian Chapter of IMA- is for health and medicine in Israel and is portrayed in British medical journals, WF for organizing the event. -
Spotted Fever Group Rickettsioses in Israel, 2010–2019
Spotted Fever Group Rickettsioses in Israel, 2010–2019 Regev Cohen, Talya Finn, Frida Babushkin, Yael Paran, Ronen Ben Ami, Alaa Atamna, Sharon Reisfeld, Gabriel Weber, Neta Petersiel, Hiba Zayyad, Eyal Leshem, Miriam Weinberger, Yasmin Maor, Nicola Makhoul, Lior Nesher, Galia Zaide, Dar Klein, Adi Beth-Din, Yafi t Atiya-Nasagi ≈ In a multicenter, nationwide, retrospective study of pa- SFGRs are associated with 20 species of Rickettsia, tients hospitalized with spotted fever group rickettsiosis of which 16 are considered human pathogens (1,2). in Israel during 2010–2019, we identifi ed 42 cases, of Recent introduction of molecular methods provided which 36 were autochthonous. The most prevalent spe- more information about SFGR agents causing human cies was the Rickettsia conorii Israeli tick typhus strain (n disease and enabled their identifi cation, for which = 33, 79%); infection with this species necessitated inten- the clinical signifi cance of some remains lacking (3). sive care for 52% of patients and was associated with a R. conorii complex, the etiologic agent of Mediterra- 30% fatality rate. A history of tick bite was rare, found for nean spotted fever, includes 4 strains: R. conorii Mal- only 5% of patients; eschar was found in 12%; and leuko- ish (cause of Mediterranean spotted fever), R. conorii cytosis was more common than leukopenia. Most (72%) Astrakhan (cause of Astrakhan fever), R. conorii In- patients resided along the Mediterranean shoreline. For 3 dian tick typhus (cause of Indian tick typhus), and R. patients, a new Rickettsia variant was identifi ed and had been acquired in eastern, mountainous parts of Israel. -
Scientific Program
The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2, -
Antibiotic Treatment for Invasive Listeriosis and Patient
Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality. -
APF Newsletter, Winter 2006 – 2007
Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs. -
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted -
P2463 Antibiotic Treatment for Invasive Listeriosis and Patient
P2463 Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein*1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav5,3, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami9,3, Miriam Weinberger10,3, Galia Rahav11,3, Yasmin Maor12,3, Michal Chowers13,3, Ran Nir-Paz2, Mical Paul8,14 1 Rambam Healthcare Campus, Haifa, Israel, 2 Hadassah University Hospital - Ein Kerem, Jerusalem, Israel, 3 Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel, 4 Soroka Medical Center, Beersheba, Israel, 5 Rabin Medical Center, Petah Tikva, Israel, 6 Shaare Zedek, Jerusalem, Israel, 7 Laniado Hospital, Netanya, Israel, 8 Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, 9 Tel Aviv Sourasky Medical Center , Tel Aviv, Israel, 10 Assaf Harofeh Medical Center, Be’er Ya’akov, Israel, 11 Sheba Medical Center, Ramat Gan, Israel, 12 Wolfson Medical Center, Holon, Israel, 13 Meir Medical Center, Kefar Sava, Israel, 14 Infectious Diseases Unit, Rambam Health Care Campus, Haifa, Israel Background: Current recommendations for treatment of invasive listeriosis suggest ampicillin-based therapy with the addition of an aminoglycoside. However, several reports have suggested higher morbidity and mortality with this regimen as compared with beta-lactam monotherapy. We aimed to evaluate the association between penicillin-aminoglycoside combination therapy and mortality in patients with invasive listeriosis while adjusting for timing of treatment onset. Materials/methods: This is a multicenter retrospective observational study of adult patients with invasive listeriosis (primary bacteremia, central nervous system [CNS] disease and pregnancy-associated listeriosis) in 11 hospitals in Israel between the years 2008-2014. We evaluated the effect of penicillin-based monotherapy compared with early combination therapy with gentamicin, defined as treatment started within 48 hours of culture results and continued for a minimum duration of 7 days. -
General Hospital Beds in Israel
Overview Date: 13 Kislev 5780, 11 December 2019 Written by: Aharon Blank, Flora Koch Davidovich | Approved by: Shelly Levy, Team Leader General hospital beds in Israel There are 45 general hospitals in Israel, a quarter of which are government-owned (nine government hospitals and two government–municipal hospitals).1 A general hospital is comprised of the following wards: internal medicine, intensive care, pediatrics, surgery, maternity wards, and intermediate care wards. Israel has a shortage of beds in general hospitals; for many years, various parties—including the State Comptroller—have noted the gap between the demands made of the system of general hospitals and the resources allocated to it, and they have called for long-term planning of the system of general hospitals in Israel.2 According to data from the Ministry of Health, in January 2019 there were 16,021 acute care beds in Israel—15,871 in general hospitals and 151 in geriatric hospitals. The rate of acute care beds in Israel has been declining since the late 1970s; as of 2019, it stands at 1.78 beds per 1,000 people, as compared to 1.88 in 2011 and 2.09 in 2005.3 Ministry of Health data from January 2019 on the geographic distribution of acute care beds indicates that nearly half are located in the central district (23.8%) and Tel Aviv (21.4%), while the remaining beds are in the Haifa district (15.2%), Jerusalem (14.5%), the northern district (12.7%) and the southern district (12.3%).4 A comparison of the rate of acute care beds in hospitals per 1,000 people in Israel to the rate in 34 OECD member states, based on data from 2017,5 indicates a decline in the rate of acute care beds in hospitals in OECD countries due to technological developments and the expansion of community healthcare services, among other things. -
Hadassah Year in Review 2019 LR
YEAR IN REVIEW 2019 Hadassah International was established in 1983 by Hadassah, the Women’s Zionist Organization of America at the initiative of Past National President Bernice S. Tannenbaum, in order to unite people of all faiths and nationalities in their mission to improve lives around the globe through their financial support of the pioneering medical healing, teaching, and research at the Hadassah Medical Organization in Jerusalem. Hadassah International spans five continents and is made up of volunteer men and women who believe that advancement and cooperation in medicine transcend politics, religion and national boundaries. The universal language of medicine allows Hadassah International to build bridges between nations and Every day let us remind help to establish research and clinical ventures between ourselves that there are the Hadassah Medical Organization and medical always new worlds to institutions around the world. conquer, new barricades to jump over. The next Hadassah Medical Organization, founded by Hadassah, decades are on the horizon the Women’s Zionist Organization of America, and let us be ready for them and may it be in a established modern healthcare in Israel. world of shalom (peace).” Bernice S. Tannenbaum Founder, Hadassah International (Pictured on Cover): Esther Tafara is chief technological engineer of the new Mount Scopus catheterization lab. A true story of bravery, the young Tafara came to Israel all alone at the age of nine as her parents and siblings were not allowed to leave Ethiopia. From the airport, she took a taxi in search of distant relatives in Jerusalem. From those shaky beginnings, Tafara went on to pursue studies in medical engineering and worked at the pulmonary department in Ein Kerem. -
Israeli Cardio-Oncology Society Virtual Meeting Preliminary Program
January 13-14, 2021 | Virtual Conference TOWARDS A COMPREHENSIVE CARDIAC-CANCER CARE Take this unique opportunity to join the ISCO 2021 conference and to effectively reach hundreds of cardiologists, oncologists and hemato-oncologists. Join us and present your research and technology to this influential and knowledgeable audience, and to have full access to all networking benefits. Conference secretariat - Dirigo Events & Conferences 3 Menorat Hamaor st. Tel-Aviv, Israel For more information, please contact: Tel: 03-7775485 | Email: [email protected] Yael Ziv Project Manager – Industry Liaison, Dirigo | Mobile: +972-54-5599821 | Email: [email protected] ISRAELI CARDIO-ONCOLOGY SOCIETY VIRTUAL MEETING PRELIMINARY PROGRAM Platinum Sponsorship Gold Sponsorship Silver Sponsorship January 13, 2021 15:45-16:00 Opening Session 15:45-15:47 Zaza Iakobishvili, Founder and Chair of the Meeting, Cardiology 15:47-15:49 Dan Gilon, Chair of the Meeting, Cardiology 15:49-15:51 David Sarid, Chair of the Meeting, Oncology 15:51-15:53 Martin Ellis, Chair of the Meeting, Hematology 15:53-15:55 Alex Lyon, ESC Cardio-Oncology Council 15:55-15:57 Bonnie Ky, JACC Cardio-Oncology 16:00-17:00 Plenary Session Chairs: Giorgio Minnotti, Faculty of Medicine and Surgery, Campus Bio-Medico University of Rome, Italy Alexander Battler, Chairman, Advisory Council on Cardiovascular Disease Management and Prevention, Ministry of Health, Israel 16:00-16:20 How to establish Cardio-Oncology collaboration Susan F. Dent, Associate Director of Breast Cancer Clinical Research, Co-Director Duke Cardio-Oncology Program, Durham, NC, USA 16:20-16:40 Guidelines in Cardio-Oncology: Gaps and Opportunities José Luis Zamorano, University Hospital Ramon Y Cajal, Madrid, Spain 16:40-17:00 Panel discussion: Future of Cardio-Oncology Richard H. -
15 July, 2021 to the Honourable: Prime Minister Naftali
15 July, 2021 To the Honourable: Prime Minister Naftali Bennett Re: Severe Warning – A Lockdown During The Upcoming Holidays Will be Catastrophic Urgent Request for a Meeting with the Prime Minister To the Honourable Prime Minister, Firstly, we wish to congratulate you on the formation of the new government. The complexity of the task you have taken on is unparalleled, certainly in these challenging times, and we wish you heartfelt success. We are hearing warnings of an impending lockdown during the upcoming holiday period, and we would like to state clearly and strongly - another lockdown will be nothing short of a catastrophe. The Public Emergency Council is a spontaneous initiative of doctors and researchers who felt that it was no longer possible to remain silent in the face of the outgoing government's steps to contain the COVID- 19 pandemic. As you can see below, among the members of the Council are individuals who constituted and still constitute the backbone of the medical establishment in this country, individuals who are at the heart of the medical consensus: four Israel Prize laureates, a Nobel laureate, experts who have managed four hospitals, a former Director General of the Ministry of Health, a HMO Director General, an IDF Deputy Chief Medical Officer, a founding member of Israel’s epidemic treatment team and an expert in disaster situations, university department heads, deans and deputy deans of medical faculties, all of whom have joined together in an extraordinary step, without any political, commercial or personal interest, in order to contribute the vast knowledge and experience which they have acquired to the relevant decision makers. -
Curriculum Vitae Dr. Toren Orly. RN, BSN, Msc, Phd 1. Personal Details
June 2019 1 Curriculum Vitae Dr. Toren Orly. RN, BSN, MSc, PhD 1. Personal Details Date of Birth: 4.7.1959 Country of birth: Israel Citizenship – Israel Number of children – 2 Military service – IDF: 1977-1979 Business address: Hadassah Medical Organization, Jerusalem, 91120 Tel: business: 02 – 6777245 Fax: 02 - 6778256 Email: [email protected] 2. Higher Education a. Academic Education 1979-1983 – Hebrew University, Jerusalem, Nursing, RN, and Bachelor in Nursing (BSN), with honors. 1985-1986 – Tel-Aviv University, Faculty of Social Sciences. Studies toward Master Degree in social sciences. 1987-1991 – Tel-Aviv University, Faculty of Business Administration. Master of Management Science (MSc.), with honors. 1995-1998 – Pittsburgh University, School of Nursing , Pittsburgh, PA, USA , Doctor of Philosophy (PhD.), with honors. Title of Master’s thesis - Relationship between job pressures and a person’s unfitness to the environment, and organizational commitment. Supervisor’s name – Prof. Mina Westman. 2 Title of Doctoral Dissertation - Mental and physical health of heart recipients as predictors of the spouse-caregivers' health one year after the transplant. Supervisor’s name – Prof. Jacqueline Dunbar-Jacob b. Advanced Academic Certification 1984 – Advanced course in Intensive Care, Sheba Academic Nursing School. 1996 – Mediation Course for medical professions, Gome, The Israeli Center for Medication practices 2008 - Good Clinical Practice in Research Certification, Hadassah Medical Organization and Hebrew University 2009 – Couching for Life, The Israeli Center for Management, Ramat Gan. 2015 – Risk Management, Technion. 2017 - Expertise in Nursing Policy and Management, Ministry of health, Profession Founder c. Clinical Practice Licensure, Registration, Certification (all active) Registered Nursing License, Hebrew University Licensed Specialty in ICU Nursing, Ministry of Health, Israel Expert in Nursing Policy and Management, Ministry of health 3.